Heart valve

Edwards' Aortic Valve With Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Surgery, Health, Clinical Trials, Cardiology, Edwards, CE, Freedom, SVD, Guy's and St Thomas' NHS Foundation Trust, Calcification, Structural heart disease, Quality of life, Heart valve, Calcium, Cardiothoracic surgery, 103rd Ohio Infantry Regiment, Patient, American Association for Thoracic Surgery, Mitral valve, Physician, NHS foundation trust, IDE, Aortic stenosis, Safety, Pharmaceutical industry, Medical imaging

Heart valves with RESILIA tissue are designed to address calcification challenges of conventional tissue valves, potentially allowing valves with RESILIA to last longer.

Key Points: 
  • Heart valves with RESILIA tissue are designed to address calcification challenges of conventional tissue valves, potentially allowing valves with RESILIA to last longer.
  • Current technologies utilizing this novel tissue include the INSPIRIS RESILIA aortic valve, the KONECT RESILIA* aortic valved conduit, the MITRIS RESILIA* mitral valve and the SAPIEN 3 Ultra RESILIA* transcatheter aortic heart valve.
  • The latest data from the COMMENCE aortic trial join a growing library of clinical studies in support of RESILIA tissue.
  • The trial is evaluating the safety and effectiveness of Edwards' bioprosthetic aortic valve with RESILIA tissue in patients ages 18 and older with diagnosed aortic valve disease and scheduled to undergo aortic valve replacement surgery.

LivaNova Reports Fourth-Quarter and Full-Year 2022 Results

Retrieved on: 
Wednesday, February 22, 2023
General Health, Neurology, Medical Devices, Health, Cardiology, Telephone, Safety, Mortality, ACS, Heart valve, Patient, Trial of the century, Growth, LivaNova, Table, Extracorporeal membrane oxygenation, Neuromodulation, ECMO, Yolo Bypass, COVID, Bank, Cryptocurrency, Pharmaceutical industry

On a U.S. GAAP basis, full-year 2022 operating loss was $76.8 million, as compared to $0.8 million for full-year 2021.

Key Points: 
  • On a U.S. GAAP basis, full-year 2022 operating loss was $76.8 million, as compared to $0.8 million for full-year 2021.
  • Adjusted operating income for full-year 2022 was $145.1 million, as compared to $154.8 million for full-year 2021.
  • On a U.S. GAAP basis, full-year 2022 diluted loss per share was $1.61, as compared to $2.68 for full-year 2021.
  • LivaNova expects revenue for full-year 2023 to grow between 3 and 5 percent on a constant-currency basis.

Global Cardiovascular Ultrasound Market Report 2022 to 2030 - Featuring GE Healthcare, Koninklijke Philips, Siemens Healthcare and Canon Medical Systems Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Health, Medical Devices, Cardiology, Degenerative disease, Heart, 2D, National Centers for Environmental Information, Modality, Baker Heart and Diabetes Institute, Moyamoya disease, National Center for Biotechnology Information, Blood, Prevalence, US, 3D, Time-invariant system, Heart valve, Growth, Marketing, Region, Doppler imaging, Medical imaging, Doppler effect

The "Cardiovascular Ultrasound Market, by Test Type, by Technology, by Modality, by End-user, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiovascular Ultrasound Market, by Test Type, by Technology, by Modality, by End-user, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • A cardiovascular ultrasound is a type of ultrasound that focuses on heart and blood vessels.
  • In echocardiogram tests, this type of imaging can be used to assess the function of various parts of cardiovascular system.
  • The emerging prevalence of cardiovascular diseases will surge the demand for cardiovascular ultrasound tests, which is expected to bolster the growth of global cardiovascular ultrasound market.

CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

Retrieved on: 
Wednesday, October 12, 2022
EuroSCORE, Risk, Population, Infection, NASDAQ, Patient, Control, IV, Annual general meeting, Inflammation, Subclinical infection, The Journal of Thoracic and Cardiovascular Surgery, University, Infective endocarditis, Endocarditis, Cytokine adsorbing column, Association, Heart failure, Incidence, European Association for Cardio-Thoracic Surgery, Heart valve, Cytosorbents Corporation, SAE, Staphylococcus, Pharmaceutical industry, Dentistry

CytoSorb is used in this patient population during open heart surgery to control cytokine storm, reduce inflammation and Staphylococcal toxins, and reverse shock.

Key Points: 
  • CytoSorb is used in this patient population during open heart surgery to control cytokine storm, reduce inflammation and Staphylococcal toxins, and reverse shock.
  • Study population: 130 consecutive patients with confirmed SAE who underwent heart valve surgery at 2 leading German Heart Centers between 01/2015 03/2022.
  • Endre Nmeth (Budapest, Hungary) presented the results of the first ever randomized, controlled trial (RCT) using CytoSorb intraoperatively during cardiac transplantation.
  • CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification.

Insights on the Cardiac Prosthetic Devices Global Market to 2027 - Featuring Abbott Vascular, Biotronik and LivaNova Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022
Health, Cardiology, Use, R, Certification, Customer support, Compound annual growth rate, Investment, Business Growth Fund, Strategic management, USD, Decision-making, COVID-19, Heart valve, Penile implant, External, Market share analysis, CAGR, Acquisition, Growth, Value, Medical device, Retail

What are the inhibiting factors and impact of COVID-19 shaping the Global Cardiac Prosthetic Devices Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Cardiac Prosthetic Devices Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cardiac Prosthetic Devices Market?
  • What is the market share of the leading vendors in the Global Cardiac Prosthetic Devices Market?
  • What modes and strategic moves are considered suitable for entering the Global Cardiac Prosthetic Devices Market?

Artivion Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in The Annals of Thoracic Surgery

Retrieved on: 
Monday, January 31, 2022
Western University, Guideline, Aspirin, Risk, Patient, The Annals of Thoracic Surgery, Warfarin, Clinical trial, FRCSC, Heart valve, INR, Bleeding, Cardiothoracic surgery, Randomized controlled trial, Research, Aorta, Stroke, MVR, Society, Inri Cristo, Society of Thoracic Surgeons, Industry, FDA, NYSE, Solution, London Health Sciences Centre, Medical imaging

ATLANTA, Jan. 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society of Thoracic Surgeons.

Key Points: 
  • ATLANTA, Jan. 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society of Thoracic Surgeons.
  • In tandem with the publication, the study results were presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons on January 30, 2022.
  • We are proud to have presented it at the Society of Thoracic Surgeons' Annual Meeting along with simultaneous publication in The Annals of Thoracic Surgery."
  • This study demonstrates that a lower target INRis safe and feasible for patients with an On-X mechanical valve in the mitralposition.

Colibri Heart Valve Initiates International CE Mark-enabling Pilot Study of Second-Generation TAVI System

Retrieved on: 
Wednesday, November 3, 2021
COVID-19, Â, Research, Center, Aortic stenosis, CE marking, CO, Patient, EOA, TAVI, Risk, Learning, Patent, Heart valve, CE, Safety, Mortality, Aortic valve, GLOBE, Sale, CERC, PPM, Physician, Medical device, Pharmaceutical industry, Medical imaging

LOUISVILLE, CO , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC , a privately held emerging medical device company, today announced the initiation of an international pilot study of the Colibri transcatheter aortic valve implantation (TAVI) system.

Key Points: 
  • LOUISVILLE, CO , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC , a privately held emerging medical device company, today announced the initiation of an international pilot study of the Colibri transcatheter aortic valve implantation (TAVI) system.
  • Commenting on his experience, Dr. Tchtch stated, I am proud to be a part of the Colibri Heart Valve study.
  • Should results from this pilot study confirm earlier clinical findings, Colibri is prepared to initiate a CE-Mark registrational study.
  • Through Colibris proprietary tissue technology and valve design, Colibri has developed a pre-mounted, pre-crimped, and pre-loaded, ready-for-use balloon expandable transcatheter aortic valve implantation (TAVI) system called the Colibri TAVI System .

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

Retrieved on: 
Monday, September 6, 2021
Anatomy, Heart, Heart valves, Organs anatomy), Mitral valve, Interventional cardiology, Heart valve, Aortic valve

Peijia Medical was founded in 2012 and its headquarter is based in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020. With "Devotion to the Heart, Reverence for Life" as its vision, Peijia Medical always puts life and safety in the first place, striving to maintain human life and health from its years of exploration in technology and its innovative persistence. Peijia Medical's strategic layout can be summarized as the "Innovation-oriented, Simultaneous Treatment of Cardiovascular and Cerebrovascular Diseases". It is dedicated to the innovation, R&D and production of high-end medical devices for structural heart disease and cerebrovascular interventions--covering aortic valve, mitral valve, tricuspid valve, surgical accessories, and diseases related to hemorrhage, ischemia and pathways in cerebrovascular intervention. It has built a relatively comprehensive array of product and solution portfolios in the field of structural heart disease and cerebrovascular interventions for use throughout China.

Key Points: 
  • Dr. Kar currently serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System, and Professor of Medicine at the David Geffen School of Medicine at UCLA.
  • He is recognized as the leading physician in developing and implementing minimally-invasive techniques in structural heart disease interventions.
  • Dr. Kar receives research grants from and is a consultant to multinational companies, such as Boston Scientific Corporation, Gore & Associates, and Abbott Vascular.
  • Peijia Medical was founded in 2012 and its headquarter is based in Suzhou,Jiangsu Province,China.

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

Retrieved on: 
Monday, September 6, 2021
Anatomy, Heart, Heart valves, Organs anatomy), Mitral valve, Interventional cardiology, Heart valve, Aortic valve

Peijia Medical was founded in 2012 and its headquarter is based in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020. With "Devotion to the Heart, Reverence for Life" as its vision, Peijia Medical always puts life and safety in the first place, striving to maintain human life and health from its years of exploration in technology and its innovative persistence. Peijia Medical's strategic layout can be summarized as the "Innovation-oriented, Simultaneous Treatment of Cardiovascular and Cerebrovascular Diseases". It is dedicated to the innovation, R&D and production of high-end medical devices for structural heart disease and cerebrovascular interventions--covering aortic valve, mitral valve, tricuspid valve, surgical accessories, and diseases related to hemorrhage, ischemia and pathways in cerebrovascular intervention. It has built a relatively comprehensive array of product and solution portfolios in the field of structural heart disease and cerebrovascular interventions for use throughout China.

Key Points: 
  • Dr. Kar currently serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System, and Professor of Medicine at the David Geffen School of Medicine at UCLA.
  • He is recognized as the leading physician in developing and implementing minimally-invasive techniques in structural heart disease interventions.
  • Dr. Kar receives research grants from and is a consultant to multinational companies, such as Boston Scientific Corporation, Gore & Associates, and Abbott Vascular.
  • Peijia Medical was founded in 2012 and its headquarter is based in Suzhou,Jiangsu Province,China.

Vivasure Medical Announces Development of Sutureless Venous Closure Device for Use in Percutaneous Transcatheter Procedures

Retrieved on: 
Thursday, July 15, 2021
Biotechnology, General Health, Surgery, Health, Cardiology, Cardiac surgery, Medical specialties, Anatomy, Clinical medicine, Mitral valve replacement, Heart valve repair, Mitral valve, Heart valve, Edwards Lifesciences, Lutembacher's syndrome

PerQseal Blue is designed exclusively for sutureless and fully absorbable large-bore venous vessel closure following percutaneous cardiovascular procedures, such transcatheter mitral valve repair or replacement (TMVR) and transcatheter tricuspid valve repair or replacement (TTVR).

Key Points: 
  • PerQseal Blue is designed exclusively for sutureless and fully absorbable large-bore venous vessel closure following percutaneous cardiovascular procedures, such transcatheter mitral valve repair or replacement (TMVR) and transcatheter tricuspid valve repair or replacement (TTVR).
  • As transcatheter procedures for mitral and tricuspid valve treatment become increasingly common, there is a growing need for new venous closure options.
  • PerQseal Blue has the potential to be the first sutureless, fully absorbable synthetic implant for large-bore venous closure following these catheter-based procedures.
  • Were thrilled to introduce PerQseal Blue to our product development portfolio as a potential new option specifically for large-bore venous closure following percutaneous cardiovascular procedures, said Andrew Glass, CEO of Vivasure Medical.